Madrigal: Rezdiffra available in the U.S. for noncirrhotic NASH

Madrigal Pharmaceuticals announced that Rezdiffra or resmetirom, is now available in the U.S. Rezdiffra is indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic NASH with moderate to advanced liver fibrosis . Continued approval for this indication may be contingent upon verification and description of clinical benefit in ongoing confirmatory trials.Bill Sibold, Chief Executive Officer of Madrigal, stated, “The introduction of Rezdiffra as the first and only FDA-approved therapy in NASH marks a turning point for Madrigal and the NASH community. Since approval, we have been partnering with healthcare providers, payers, and patient advocates to build new care pathways that will help patients access Rezdiffra and achieve their treatment goals. Our field teams are fully deployed, our specialty pharmacy network is processing prescriptions, our supply chain is fully operational, and most importantly, the first patients are now receiving Rezdiffra.”